• Hypertension

Cleviprex Generic Name & Formulations

General Description

Clevidipine butyrate emulsion 0.5mg/mL; soln for IV infusion; contains lipids 0.2g/mL (soybean oil, egg phospholipids).

Pharmacological Class

Calcium channel blocker (CCB) (dihydropyridine).

How Supplied

Single-use vials (50mL, 100mL)—10


Generic Availability


Cleviprex Indications


To reduce blood pressure when oral therapy is not feasible or desirable.

Cleviprex Dosage and Administration


≥18yrs: Individualize; titrate. Give by IV infusion. Initially 1–2mg/hr; double dose at 90sec intervals until BP approaches goal, then titrate slower (adjust at 5–10min intervals). Dose increases of 1–2mg/hr results in systolic BP lowering of about 2–4mmHg. Maintenance: 4–6mg/hr; usual max 16–32mg/hr. Do not exceed 1000mL (21mg/hr for 24hrs) due to lipid load. Switch to oral therapy when indicated.


<18yrs: not established.

Cleviprex Contraindications


Egg or soy allergy. Defective lipid metabolism (eg, pathologic hyperlipemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia). Severe aortic stenosis.

Cleviprex Boxed Warnings

Not Applicable

Cleviprex Warnings/Precautions


Maintain aseptic technique. Monitor BP and pulse during infusion and until stabilized. Heart failure (monitor). Monitor for rebound hypertension for at least 8hrs after stopping infusion (if not given other antihypertensives after prolonged infusion). Avoid abrupt cessation of any β-blocker treatment. Pheochromocytoma. Elderly. Labor & delivery. Pregnancy. Nursing mothers.

Cleviprex Pharmacokinetics

See Literature

Cleviprex Interactions

Cleviprex Adverse Reactions

Adverse Reactions

Headache, nausea, vomiting; hypotension, reflex tachycardia (slow infusion if occurs, do not use beta-blocker); rare: myocardial infarction, cardiac arrest, syncope, dyspnea.

Cleviprex Clinical Trials

See Literature

Cleviprex Note

Not Applicable

Cleviprex Patient Counseling

See Literature